首页 > 最新文献

African Journal of Thoracic and Critical Care Medicine最新文献

英文 中文
Bridging hope: South Africa’s ECMO reporting journey begins 架起希望之桥南非开始 ECMO 报告之旅
Q3 Medicine Pub Date : 2023-11-29 DOI: 10.7196/ajtccm.2023.v29i4.1727
G. Calligaro, D. Thomson
-
-
{"title":"Bridging hope: South Africa’s ECMO reporting journey begins","authors":"G. Calligaro, D. Thomson","doi":"10.7196/ajtccm.2023.v29i4.1727","DOIUrl":"https://doi.org/10.7196/ajtccm.2023.v29i4.1727","url":null,"abstract":"<jats:p>-</jats:p>","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139211563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The hidden epidemic of post-tuberculosis bronchiectasis 结核病后支气管扩张的隐性流行病
Q3 Medicine Pub Date : 2023-11-29 DOI: 10.7196/ajtccm.2023.v29i4.1728
R. Perumal
-
-
{"title":"The hidden epidemic of post-tuberculosis bronchiectasis","authors":"R. Perumal","doi":"10.7196/ajtccm.2023.v29i4.1728","DOIUrl":"https://doi.org/10.7196/ajtccm.2023.v29i4.1728","url":null,"abstract":"<jats:p>-</jats:p>","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139209188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ventilator-associated pneumonia is ubiquitous and troublesome 呼吸机相关性肺炎无处不在,令人头疼
Q3 Medicine Pub Date : 2023-11-29 DOI: 10.7196/ajtccm.2023.v29i4.1611
R. I. Raine
{"title":"Ventilator-associated pneumonia is ubiquitous and troublesome","authors":"R. I. Raine","doi":"10.7196/ajtccm.2023.v29i4.1611","DOIUrl":"https://doi.org/10.7196/ajtccm.2023.v29i4.1611","url":null,"abstract":"","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139214683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-cystic fibrosis bronchiectasis: A single-centre retrospective study in Johannesburg, South Africa 非囊性纤维化支气管扩张症:南非约翰内斯堡单中心回顾性研究
Q3 Medicine Pub Date : 2023-11-29 DOI: 10.7196/ajtccm.2023.v29i4.1017
G. Titus, MMed Fcp SA MB ChB, S. Hassanali, Mbbs MMed Feldman BSc, DSc DMed honoris causa MB BCh
Background. Bronchiectasis, once rarely encountered, appears to be increasing in prevalence in South Africa (SA) and globally. There is a lack of published data on non-cystic fibrosis (CF) bronchiectasis, specifically in low- to middle-income countries, despite the high rates of risk factors such as HIV, pulmonary tuberculosis, and other infections. Objectives. Given this lack of data, to review the characteristics of adult patients with non-CF bronchiectasis at a tertiary academic hospital in Johannesburg, SA. Methods. This was a single-centre, retrospective record review, including all cases of non-CF bronchiectasis that were in the records of the adult pulmonology clinic at Charlotte Maxeke Johannesburg Academic Hospital as of April 2017. Results. There were 197 patients, with a slight predominance of males, and the patients were generally young. The HIV rate was higher than the national average (34.8% v. 13.7%), and the HIV-positive patients had a high TB prevalence (86.9%). Pseudomonas spp. were cultured from sputum in 15.3% of cases. Fewer than half of the cohort had the diagnosis of bronchiectasis confirmed by high-resolution chest tomography. Airway obstruction (forced expiratory volume in 1 second/forced vital capacity ratio <70%) was observed in 47.0% of patients. Treatment with a short-acting beta-2-agonist was prescribed in 62.9%, a long-acting beta-2-agonist in 43.6% and inhaled corticosteroids in 51.3%. Antibiotic therapy during exacerbations was used in 44.2%, mainly amoxycillin-clavulanate (66.7%). Conclusion. While single centre and retrospective, this study adds to the data on non-CF bronchiectasis in sub-Saharan Africa and should encourage further research to increase our understanding of adult non-CF bronchiectasis in SA.
背景。支气管扩张症曾经很少发生,但在南非和全球的发病率似乎正在上升。尽管HIV、肺结核和其他感染等风险因素的发病率很高,但缺乏有关非囊性纤维化(CF)支气管扩张症的公开数据,特别是在中低收入国家。研究目的。鉴于数据的缺乏,回顾南澳约翰内斯堡一家三级学术医院非囊性纤维化支气管扩张症成年患者的特征。方法。这是一项单中心、回顾性记录审查,包括夏洛特-麦克斯克约翰内斯堡学术医院成人肺病诊所截至 2017 年 4 月记录在案的所有非慢性支气管炎支气管扩张症病例。结果。共有197名患者,男性略占多数,患者普遍年轻。艾滋病毒感染率高于全国平均水平(34.8% 对 13.7%),艾滋病毒阳性患者的结核病发病率较高(86.9%)。15.3%的病例从痰中培养出假单胞菌属。经高分辨率胸部断层扫描确诊为支气管扩张症的患者不到半数。47.0%的患者出现气道阻塞(1秒内用力呼气量/用力肺活量比值小于70%)。62.9%的患者接受了短效β-2-受体激动剂治疗,43.6%的患者接受了长效β-2-受体激动剂治疗,51.3%的患者接受了吸入皮质类固醇治疗。44.2%的患者在病情加重时使用抗生素治疗,主要是阿莫西林-克拉维酸(66.7%)。结论虽然该研究是单中心和回顾性的,但它增加了撒哈拉以南非洲非中风支气管扩张症的数据,应鼓励进一步研究,以增加我们对撒哈拉以南非洲成人非中风支气管扩张症的了解。
{"title":"Non-cystic fibrosis bronchiectasis: A single-centre retrospective study in Johannesburg, South Africa","authors":"G. Titus, MMed Fcp SA MB ChB, S. Hassanali, Mbbs MMed Feldman BSc, DSc DMed honoris causa MB BCh","doi":"10.7196/ajtccm.2023.v29i4.1017","DOIUrl":"https://doi.org/10.7196/ajtccm.2023.v29i4.1017","url":null,"abstract":"Background. Bronchiectasis, once rarely encountered, appears to be increasing in prevalence in South Africa (SA) and globally. There is a lack of published data on non-cystic fibrosis (CF) bronchiectasis, specifically in low- to middle-income countries, despite the high rates of risk factors such as HIV, pulmonary tuberculosis, and other infections. Objectives. Given this lack of data, to review the characteristics of adult patients with non-CF bronchiectasis at a tertiary academic hospital in Johannesburg, SA. Methods. This was a single-centre, retrospective record review, including all cases of non-CF bronchiectasis that were in the records of the adult pulmonology clinic at Charlotte Maxeke Johannesburg Academic Hospital as of April 2017. Results. There were 197 patients, with a slight predominance of males, and the patients were generally young. The HIV rate was higher than the national average (34.8% v. 13.7%), and the HIV-positive patients had a high TB prevalence (86.9%). Pseudomonas spp. were cultured from sputum in 15.3% of cases. Fewer than half of the cohort had the diagnosis of bronchiectasis confirmed by high-resolution chest tomography. Airway obstruction (forced expiratory volume in 1 second/forced vital capacity ratio <70%) was observed in 47.0% of patients. Treatment with a short-acting beta-2-agonist was prescribed in 62.9%, a long-acting beta-2-agonist in 43.6% and inhaled corticosteroids in 51.3%. Antibiotic therapy during exacerbations was used in 44.2%, mainly amoxycillin-clavulanate (66.7%). Conclusion. While single centre and retrospective, this study adds to the data on non-CF bronchiectasis in sub-Saharan Africa and should encourage further research to increase our understanding of adult non-CF bronchiectasis in SA.","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139209220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracorporeal membrane oxygenation in South Africa: Experience from a single centre in the private sector. 南非的体外膜肺氧合:一家私营中心的经验。
Q3 Medicine Pub Date : 2023-11-27 eCollection Date: 2023-01-01 DOI: 10.7196/AJTCCM.2023.v29i4.211
N L F van Zijl, J T Janson, M Sussman, A Geldenhuys

Background: Extracorporeal membrane oxygenation (ECMO) is an advanced, resource-intensive technology used in a limited capacity in South Africa (SA). Minimal data on the use of ECMO in SA are available.

Objectives: To describe the indications, early outcome and comorbidities of patients placed on ECMO in the highest-volume ECMO centre in SA.

Methods: We performed a single-centre retrospective review of all adult patients supported with any form of ECMO from August 2016 to December 2018. Operative and clinical records were reviewed. The primary objective of this study was to review the outcome of patients placed on ECMO in the form of survival to hospital discharge. The secondary objectives were to identify population-specific comorbidities and indications for ECMO that could be associated with non-survival and to compare outcome with known risk scores in the form of the Respiratory ECMO Survival Prediction (RESP) and Survival After Venoarterial ECMO (SAVE) scores.

Results: One hundred and seven patients were identified. The primary indication for ECMO was respiratory support in 78 patients and cardiac support in 29 patients. Forty-seven patients were discharged from hospital, with a 44.0% overall survival rate. Gender (p=0.039), age (p=0.019) and hypertension (p=0.022) were associated with death in univariate logistic regression analysis. However, after adjusting for potential confounding in multivariate logistic regression analysis, the association was no longer significant. In the all respiratory support group, patients in risk class IV had better than predicted survival according to the RESP score, while risk classes I, II and III had worse than predicted survival. In the circulatory support group, all risk classes had worse than predicted survival according to the SAVE score.

Conclusion: We report ECMO outcomes in SA for the first time. We identified very high mortality rates for patients transferred on ECMO from other facilities and for patients converted from venovenous ECMO to venoarterial ECMO. Although our outcomes were comparable in some of the risk classes, further external validation of the SAVE and RESP scores will be needed to compare our outcomes with these scores.

Study synopsis: What the study adds. We report on extracorporeal membrane oxygenation (ECMO) outcomes in South Africa for the first time. We identified a high mortality rate in patients transferred on ECMO from other facilities, and in patients converted from venovenous ECMO to venoarterial ECMO.Implications of the findings. Transferred patients had a high mortality rate. The reason for this should be further investigated and may highlight the need for possible protocols to assist with appropriate timing of patient transfers and possible earlier intervention or transfer.

背景:体外膜肺氧合(ECMO)是一种先进的资源密集型技术,在南非的使用能力有限。有关 ECMO 在南非使用情况的数据极少:目的:描述在南非人数最多的 ECMO 中心接受 ECMO 治疗的患者的适应症、早期疗效和合并症:我们对 2016 年 8 月至 2018 年 12 月期间接受任何形式 ECMO 支持的所有成人患者进行了单中心回顾性审查。对手术和临床记录进行了回顾。本研究的首要目标是回顾接受 ECMO 治疗的患者出院后的存活率。次要目标是确定可能与非存活率相关的人群特异性合并症和 ECMO 适应症,并将结果与已知的风险评分(即呼吸 ECMO 存活率预测 (RESP) 和静脉 ECMO 后存活率 (SAVE) 评分)进行比较:结果:共发现 107 名患者。78 名患者 ECMO 的主要适应症是呼吸支持,29 名患者是心脏支持。47 名患者出院,总存活率为 44.0%。在单变量逻辑回归分析中,性别(p=0.039)、年龄(p=0.019)和高血压(p=0.022)与死亡有关。然而,在多变量逻辑回归分析中调整了潜在的混杂因素后,这种关联不再显著。在所有呼吸支持组中,根据 RESP 评分,风险等级 IV 的患者生存率高于预测值,而风险等级 I、II 和 III 的患者生存率低于预测值。在循环支持组中,根据 SAVE 评分,所有风险分级的存活率均低于预测值:我们首次报告了南澳州的 ECMO 结果。我们发现,从其他机构转入 ECMO 的患者以及从静脉 ECMO 转为静脉 ECMO 的患者死亡率非常高。虽然我们的结果在某些风险等级中具有可比性,但还需要对 SAVE 和 RESP 评分进行进一步的外部验证,以便将我们的结果与这些评分进行比较。我们首次报告了南非的体外膜肺氧合(ECMO)结果。我们发现,从其他机构转入 ECMO 的患者以及从静脉 ECMO 转为静脉动脉 ECMO 的患者死亡率很高。转院患者的死亡率较高。转院患者的死亡率较高,其原因有待进一步研究,并强调需要制定可能的协议,以协助选择适当的患者转院时机,并尽早进行干预或转院。
{"title":"Extracorporeal membrane oxygenation in South Africa: Experience from a single centre in the private sector.","authors":"N L F van Zijl, J T Janson, M Sussman, A Geldenhuys","doi":"10.7196/AJTCCM.2023.v29i4.211","DOIUrl":"10.7196/AJTCCM.2023.v29i4.211","url":null,"abstract":"<p><strong>Background: </strong>Extracorporeal membrane oxygenation (ECMO) is an advanced, resource-intensive technology used in a limited capacity in South Africa (SA). Minimal data on the use of ECMO in SA are available.</p><p><strong>Objectives: </strong>To describe the indications, early outcome and comorbidities of patients placed on ECMO in the highest-volume ECMO centre in SA.</p><p><strong>Methods: </strong>We performed a single-centre retrospective review of all adult patients supported with any form of ECMO from August 2016 to December 2018. Operative and clinical records were reviewed. The primary objective of this study was to review the outcome of patients placed on ECMO in the form of survival to hospital discharge. The secondary objectives were to identify population-specific comorbidities and indications for ECMO that could be associated with non-survival and to compare outcome with known risk scores in the form of the Respiratory ECMO Survival Prediction (RESP) and Survival After Venoarterial ECMO (SAVE) scores.</p><p><strong>Results: </strong>One hundred and seven patients were identified. The primary indication for ECMO was respiratory support in 78 patients and cardiac support in 29 patients. Forty-seven patients were discharged from hospital, with a 44.0% overall survival rate. Gender (p=0.039), age (p=0.019) and hypertension (p=0.022) were associated with death in univariate logistic regression analysis. However, after adjusting for potential confounding in multivariate logistic regression analysis, the association was no longer significant. In the all respiratory support group, patients in risk class IV had better than predicted survival according to the RESP score, while risk classes I, II and III had worse than predicted survival. In the circulatory support group, all risk classes had worse than predicted survival according to the SAVE score.</p><p><strong>Conclusion: </strong>We report ECMO outcomes in SA for the first time. We identified very high mortality rates for patients transferred on ECMO from other facilities and for patients converted from venovenous ECMO to venoarterial ECMO. Although our outcomes were comparable in some of the risk classes, further external validation of the SAVE and RESP scores will be needed to compare our outcomes with these scores.</p><p><strong>Study synopsis: </strong><b>What the study adds.</b> We report on extracorporeal membrane oxygenation (ECMO) outcomes in South Africa for the first time. We identified a high mortality rate in patients transferred on ECMO from other facilities, and in patients converted from venovenous ECMO to venoarterial ECMO.<b>Implications of the findings.</b> Transferred patients had a high mortality rate. The reason for this should be further investigated and may highlight the need for possible protocols to assist with appropriate timing of patient transfers and possible earlier intervention or transfer.</p>","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139492871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should a drain be inserted? 是否需要插入引流管?
Q3 Medicine Pub Date : 2023-11-27 eCollection Date: 2023-01-01
M J Mpe
{"title":"Should a drain be inserted?","authors":"M J Mpe","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139492874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ventilator-associated pneumonia in an academic intensive care unit in Johannesburg, South Africa. 南非约翰内斯堡一家学术重症监护病房的呼吸机相关肺炎。
Q3 Medicine Pub Date : 2023-11-27 eCollection Date: 2023-01-01 DOI: 10.7196/AJTCCM.2023.v29i4.154
S Mazwi, S A van Blydenstein, M Mukansi

Background: Ventilator-associated pneumonia (VAP) has an estimated incidence of 10 - 41.5 events per 1 000 ventilator days in developing countries, and carries high mortality. Little is known about the incidence and outcomes of VAP in Johannesburg, South Africa.

Objectives: To describe VAP in a tertiary public hospital in Johannesburg, assess the microbiological pathogens associated with VAP (both early and late), and outline the outcomes of these patients.

Methods: The study was a retrospective record review of patients admitted to the Helen Joseph Hospital intensive care unit (ICU) between March 2013 and January 2016.

Results: VAP developed in 24/842 ventilated patients (2.9%; 95% confidence interval (CI) 1.8 - 4.2), with an incidence of 23 events per 1 000 ventilator days, during the study period. Of these patients, one-third (29.2%) died and 70.8% were discharged from the ICU. Late-onset VAP (onset ≥5 days after intubation, incidence 45.8%) was associated with higher mortality (54.6%) than early-onset VAP (onset within 4 days after intubation, incidence 54.2% and mortality 7.7%). Commonly isolated organisms were Klebsiellai pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. There was a trend towards an increased risk of multidrug-resistant organisms with late-onset VAP (adjusted relative risk 2.26; 95% CI 0.92 - 5.57; p=0.077) and airway access through a tracheostomy (relative risk 1.68; 95% CI 0.78 - 3.57).

Conclusion: The study showed a low to moderate incidence of VAP of 23 events per 1 000 ventilator days. A tracheostomy and late-onset VAP were associated with infection by drug-resistant organisms. The mortality rate was 29.2% in this setting, with a seven-fold increase in mortality with late-onset VAP.

Study synopsis: What the study adds. This study helps to improve understanding of the incidence of ventilator-associated pneumonia in South Africa, a low- to middle-income country, and the commonly encountered causative pathogens. It indicates the importance of a short intensive care unit (ICU) stay as a target outcome for prevention of nosocomial infections and other complications.Implications of the findings. The study: reinforces the importance of preventive mesures in the ICU and keeping up to date with the evidence in the fieldhighlights the importance of knowing local microbial resistance patterns in order to develop precise antibiogramsshows the need for research in ICU care for people of advanced age, and the impact that admission rationing has on our ICU populations.

背景:在发展中国家,呼吸机相关肺炎(VAP)的发病率估计为每千个呼吸机日 10-41.5 例,死亡率很高。在南非约翰内斯堡,人们对 VAP 的发病率和结果知之甚少:描述约翰内斯堡一家三级公立医院的 VAP 情况,评估与 VAP 相关的微生物病原体(早期和晚期),并概述这些患者的治疗效果:研究对2013年3月至2016年1月期间入住海伦-约瑟夫医院重症监护室(ICU)的患者进行了回顾性记录审查:在研究期间,24/842 名呼吸机患者发生了 VAP(2.9%;95% 置信区间 (CI) 1.8 - 4.2),每千个呼吸机日发生率为 23 例。这些患者中有三分之一(29.2%)死亡,70.8%从重症监护室出院。晚发型 VAP(插管后≥5 天发病,发病率为 45.8%)的死亡率(54.6%)高于早发型 VAP(插管后 4 天内发病,发病率为 54.2%,死亡率为 7.7%)。常见的分离菌为肺炎克雷伯氏菌、鲍曼不动杆菌和铜绿假单胞菌。晚发型 VAP(调整后相对风险为 2.26;95% CI 为 0.92 - 5.57;P=0.077)和通过气管造口进入气道(相对风险为 1.68;95% CI 为 0.78 - 3.57)的多重耐药菌风险呈上升趋势:研究显示,VAP 的发生率为中低水平,每 1 000 个呼吸机日中有 23 例。气管切开术和晚期 VAP 与耐药菌感染有关。在这种情况下,死亡率为 29.2%,晚期 VAP 的死亡率增加了七倍。这项研究有助于进一步了解南非这个中低收入国家的呼吸机相关肺炎发病率以及常见的致病病原体。研究结果的意义。这项研究:加强了重症监护室预防措施的重要性,并与该领域的最新证据保持同步;强调了了解当地微生物耐药性模式的重要性,以便制定精确的抗生素图谱;显示了对高龄老人重症监护室护理进行研究的必要性,以及入院配给对重症监护室人群的影响。
{"title":"Ventilator-associated pneumonia in an academic intensive care unit in Johannesburg, South Africa.","authors":"S Mazwi, S A van Blydenstein, M Mukansi","doi":"10.7196/AJTCCM.2023.v29i4.154","DOIUrl":"https://doi.org/10.7196/AJTCCM.2023.v29i4.154","url":null,"abstract":"<p><strong>Background: </strong>Ventilator-associated pneumonia (VAP) has an estimated incidence of 10 - 41.5 events per 1 000 ventilator days in developing countries, and carries high mortality. Little is known about the incidence and outcomes of VAP in Johannesburg, South Africa.</p><p><strong>Objectives: </strong>To describe VAP in a tertiary public hospital in Johannesburg, assess the microbiological pathogens associated with VAP (both early and late), and outline the outcomes of these patients.</p><p><strong>Methods: </strong>The study was a retrospective record review of patients admitted to the Helen Joseph Hospital intensive care unit (ICU) between March 2013 and January 2016.</p><p><strong>Results: </strong>VAP developed in 24/842 ventilated patients (2.9%; 95% confidence interval (CI) 1.8 - 4.2), with an incidence of 23 events per 1 000 ventilator days, during the study period. Of these patients, one-third (29.2%) died and 70.8% were discharged from the ICU. Late-onset VAP (onset ≥5 days after intubation, incidence 45.8%) was associated with higher mortality (54.6%) than early-onset VAP (onset within 4 days after intubation, incidence 54.2% and mortality 7.7%). Commonly isolated organisms were <i>Klebsiellai</i> <i>pneumoniae</i>, <i>Acinetobacter</i> <i>baumannii</i> and <i>Pseudomonas</i> aeruginosa. There was a trend towards an increased risk of multidrug-resistant organisms with late-onset VAP (adjusted relative risk 2.26; 95% CI 0.92 - 5.57; p=0.077) and airway access through a tracheostomy (relative risk 1.68; 95% CI 0.78 - 3.57).</p><p><strong>Conclusion: </strong>The study showed a low to moderate incidence of VAP of 23 events per 1 000 ventilator days. A tracheostomy and late-onset VAP were associated with infection by drug-resistant organisms. The mortality rate was 29.2% in this setting, with a seven-fold increase in mortality with late-onset VAP.</p><p><strong>Study synopsis: </strong><b>What the study adds.</b> This study helps to improve understanding of the incidence of ventilator-associated pneumonia in South Africa, a low- to middle-income country, and the commonly encountered causative pathogens. It indicates the importance of a short intensive care unit (ICU) stay as a target outcome for prevention of nosocomial infections and other complications.<b>Implications of the findings.</b> The study: reinforces the importance of preventive mesures in the ICU and keeping up to date with the evidence in the fieldhighlights the importance of knowing local microbial resistance patterns in order to develop precise antibiogramsshows the need for research in ICU care for people of advanced age, and the impact that admission rationing has on our ICU populations.</p>","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10699432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A point-prevalence study of body mass indices in HIV-positive and HIV-negative patients admitted to hospital with COVID-19 in South Africa. 南非hiv阳性和hiv阴性COVID-19住院患者体重指数点流行研究
Q3 Medicine Pub Date : 2023-09-19 eCollection Date: 2023-01-01 DOI: 10.7196/AJTCCM.2023.v29i3.660
A Parker, A G B Broadhurst, M S Moolla, L Amien, R Ahmed, J J Taljaard, G Meintjes, P Nyasulu, C F N Koegelenberg

Background: Obesity is now well recognised as a risk factor for severe COVID-19, but the true prevalence of obesity in hospitalised adults with COVID-19 remains unclear because formal body mass indices (BMIs) are not routinely measured on admission.

Objectives: To describe the true prevalence of obesity measured by the BMI, and associated comorbidities, in patients hospitalised with severe COVID-19, including people with HIV (PWH).

Methods: We conducted a point-prevalence study of measured BMI in consecutive patients with severe COVID-19 admitted to the medical COVID-19 wards in a tertiary academic hospital in Cape Town, South Africa (SA). Patients were enrolled over a 2-week period during the peak of the first COVID-19 wave in SA.

Results: We were able to measure the BMI in 122 of the 146 patients admitted during the study period. The prevalence of HIV was 20% (n=24/122). Most of the participants were overweight or obese (n=104; 85%), and 84 (68.9%) met criteria for obesity. The mean (standard deviation) BMI was 33 (7.5), and 34.5 (9.1) in PWH. Of PWH, 83% (n=20/24) were overweight or obese and 75% (n=18) met criteria for obesity. Multimorbidity was present in 22 (92%) of PWH.

Conclusion: We found that most patients, including PWH, met criteria for being overweight or obese. The high prevalence of obesity in PWH and severe COVID-19 reinforces the need for targeted management of non-communicable diseases, including obesity, in PWH.

Study synopsis: What the study adds. We found that the true prevalence of obesity, including in people with HIV (PWH), measured with the formal body mass index in hospitalised patients with severe COVID-19 was much higher than reported previously.Multimorbidity was present in over half of all patients, and in 92% of PWH. Implications of the findings. Urgent public health measures are required to tackle the rise in obesity, including in low- and middle-income countries.HIV care must integrate management of non-communicable diseases, including obesity.The pathogenic mechanism of the link between obesity and severe COVID-19 needs further research.

背景:肥胖现已被公认为严重COVID-19的一个危险因素,但由于入院时没有常规测量正式的体重指数(bmi),因此COVID-19住院成人中肥胖的真实患病率仍不清楚。目的:描述重症COVID-19住院患者(包括艾滋病毒感染者)的BMI测量的肥胖真实患病率及其相关合并症。方法:我们对南非开普敦一家三级学术医院COVID-19医学病房收治的连续重症COVID-19患者进行了点流行BMI测量研究。在南非第一波COVID-19高峰期间,患者在两周内入组。结果:在研究期间,我们能够测量146例入院患者中的122例的BMI。艾滋病毒感染率为20% (n=24/122)。大多数参与者超重或肥胖(n=104;85%), 84例(68.9%)符合肥胖标准。BMI均值(标准差)为33 (7.5),PWH组为34.5(9.1)。PWH患者中,83% (n=20/24)超重或肥胖,75% (n=18)符合肥胖标准。22例(92%)PWH存在多重发病。结论:我们发现大多数患者,包括PWH,符合超重或肥胖标准。妇女健康状况中肥胖的高流行率和COVID-19的严重流行,加强了对妇女健康状况中包括肥胖在内的非传染性疾病进行有针对性管理的必要性。研究简介:研究补充了什么。我们发现,用严重COVID-19住院患者的正式体重指数测量的肥胖的真实患病率,包括艾滋病毒感染者(PWH),远高于之前报道的水平。超过一半的患者和92%的PWH患者存在多重发病。研究结果的含义。需要采取紧急公共卫生措施,解决肥胖人数上升的问题,包括在低收入和中等收入国家。艾滋病毒护理必须与包括肥胖在内的非传染性疾病的管理相结合。肥胖与重症COVID-19之间联系的致病机制有待进一步研究。
{"title":"A point-prevalence study of body mass indices in HIV-positive and HIV-negative patients admitted to hospital with COVID-19 in South Africa.","authors":"A Parker, A G B Broadhurst, M S Moolla, L Amien, R Ahmed, J J Taljaard, G Meintjes, P Nyasulu, C F N Koegelenberg","doi":"10.7196/AJTCCM.2023.v29i3.660","DOIUrl":"https://doi.org/10.7196/AJTCCM.2023.v29i3.660","url":null,"abstract":"<p><strong>Background: </strong>Obesity is now well recognised as a risk factor for severe COVID-19, but the true prevalence of obesity in hospitalised adults with COVID-19 remains unclear because formal body mass indices (BMIs) are not routinely measured on admission.</p><p><strong>Objectives: </strong>To describe the true prevalence of obesity measured by the BMI, and associated comorbidities, in patients hospitalised with severe COVID-19, including people with HIV (PWH).</p><p><strong>Methods: </strong>We conducted a point-prevalence study of measured BMI in consecutive patients with severe COVID-19 admitted to the medical COVID-19 wards in a tertiary academic hospital in Cape Town, South Africa (SA). Patients were enrolled over a 2-week period during the peak of the first COVID-19 wave in SA.</p><p><strong>Results: </strong>We were able to measure the BMI in 122 of the 146 patients admitted during the study period. The prevalence of HIV was 20% (n=24/122). Most of the participants were overweight or obese (n=104; 85%), and 84 (68.9%) met criteria for obesity. The mean (standard deviation) BMI was 33 (7.5), and 34.5 (9.1) in PWH. Of PWH, 83% (n=20/24) were overweight or obese and 75% (n=18) met criteria for obesity. Multimorbidity was present in 22 (92%) of PWH.</p><p><strong>Conclusion: </strong>We found that most patients, including PWH, met criteria for being overweight or obese. The high prevalence of obesity in PWH and severe COVID-19 reinforces the need for targeted management of non-communicable diseases, including obesity, in PWH.</p><p><strong>Study synopsis: </strong>What the study adds. We found that the true prevalence of obesity, including in people with HIV (PWH), measured with the formal body mass index in hospitalised patients with severe COVID-19 was much higher than reported previously.Multimorbidity was present in over half of all patients, and in 92% of PWH. Implications of the findings. Urgent public health measures are required to tackle the rise in obesity, including in low- and middle-income countries.HIV care must integrate management of non-communicable diseases, including obesity.The pathogenic mechanism of the link between obesity and severe COVID-19 needs further research.</p>","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Silicosis and silicotuberculosis: Ancient diseases that are still not conquered. 矽肺和矽肺:仍未被征服的古老疾病。
Q3 Medicine Pub Date : 2023-09-19 eCollection Date: 2023-01-01 DOI: 10.7196/AJTCCM.2023.v29i3.1495
W A J Meintjes
{"title":"Silicosis and silicotuberculosis: Ancient diseases that are still not conquered.","authors":"W A J Meintjes","doi":"10.7196/AJTCCM.2023.v29i3.1495","DOIUrl":"10.7196/AJTCCM.2023.v29i3.1495","url":null,"abstract":"","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vitamin B12 deficiency presenting with pulmonary embolism: An unusual presentation 维生素B12缺乏表现为肺栓塞:一种不寻常的表现
Q3 Medicine Pub Date : 2023-09-19 DOI: 10.7196/ajtccm.2023.v29i3.285
L W Ndaba, S A Van Blydenstein, K E Hodkinson
-
-
{"title":"Vitamin B12 deficiency presenting with pulmonary embolism: An unusual presentation","authors":"L W Ndaba, S A Van Blydenstein, K E Hodkinson","doi":"10.7196/ajtccm.2023.v29i3.285","DOIUrl":"https://doi.org/10.7196/ajtccm.2023.v29i3.285","url":null,"abstract":"-","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135108527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
African Journal of Thoracic and Critical Care Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1